Dan Mazaisz

Company: Kyverna Therapeutics, Inc.

Job title: Chief Business Officer

Bio:

Dan Maziasz is Chief Business Officer at Kyverna Therapeutics, and responsible for leading corporate strategy, business development, alliance management, and commercial activities. Prior to joining Kyverna, Dan served as Chief Business Officer at Atara Biotherapeutics, the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Before his time at Atara, Dan was Vice President, Corporate Strategy and Business Development at Kite Pharma, a global cell therapy leader, prior to its acquisition by Gilead. Dan also spent more than a decade at Amgen, where he held roles of increasing responsibility in the US, Europe, and Asia. 

 

Seminars:

Unlocking New Immune Pathways: Discussing B-Cell Depletion & Beyond in Autoimmune Therapy 9:10 am

Discussing the latest B-cell depletion data across diseases to assess effectiveness and potential for expansion into dermatological diseases such as psoriasis Evaluating if B-cell depletion remains the most promising approach and exploring the potential to move beyond B-cell targeting (including, Mast Cells, T-cells, Macrophages, Myeloid Cells and more) Exploring immune cell depletion across disease indications…Read more

day: Day Two